IMARC Group has published a market research report titled "United States Gene Therapy Market Report by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide Gene, Deficiency, Growth Factors, Receptors, and Others), Vector Type (Viral Vector, Non-Viral Techniques), Delivery Method (In-Vivo Gene Therapy, Ex-Vivo Gene Therapy), Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Others), and Region 2024-2032", The United States gene therapy market size is projected to exhibit a growth rate (CAGR) of 12.2% during 2024-2032.

The advancements in genetic science as well as the rising focus on biotechnology research are the factors responsible for the growth of the United States gene therapy market. Additionally, gene therapy offers revolutionary treatments by introducing, removing, or altering genetic material within cells for a wide range of genetic and also acquired diseases, including cancer, rare disorders, and cardiovascular diseases, which is fueling the market. Besides this, the approval by the FDA of several gene therapies in recent years has bolstered the market, showcasing the potential for these treatments to provide cures for previously untreatable conditions. Moreover, the increasing occurrence of genetic disorders and high investment in healthcare research by both government authorities and private sectors are further propelling the development and acceptance of gene therapies. 

Grab a sample PDF of this report: https://www.imarcgroup.com/united-states-gene-therapy-market/requestsample

United States Gene Therapy Market Trends and Drivers:

Technological innovations in delivery mechanisms, such as viral vector systems and CRISPR gene-editing technology, have significantly enhanced the efficiency and precision of gene therapies. These advancements reduce treatment risks and improve therapeutic outcomes, increasing the attractiveness of gene therapies to patients and healthcare providers, which is acting as another growth-inducing factor. Furthermore, the market also faces challenges such as high treatment costs and complex manufacturing processes that can limit accessibility. In line with this, efforts to streamline production and the development of scalable technologies are crucial for broadening the availability of these therapies, which is anticipated to drive the United States gene therapy market over the forecasted period.

Report Segmentation:

The report has segmented the market into the following categories:

Gene Type Insights:

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide Gene
• Deficiency
• Growth Factors
• Receptors
• Others

Vector Type Insights:

• Viral Vector 
  • Adenoviruses
  • Lentiviruses
  • Retroviruses
  • Adeno-Associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • nia ViruVaccis
  • Others
•  Non-Viral Techniques
  • Naked and Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others 

Delivery Method Insights:

• In-Vivo Gene Therapy
• Ex-Vivo Gene Therapy

Application Insights:

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Disease
• Others

Regional Insights:

• Northeast
• Midwest
• South
• West

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel NoD) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163